To develop and conduct clinical trials aimed at improving the treatment and prevention of cancer with the ultimate goal of reducing morbidity and mortality from this disease.

About Us

The Canadian Cancer Trials Group is a cooperative oncology group which carries out clinical trials in cancer therapy, supportive care and prevention across Canada and internationally. It is one of the national programmes and networks of the Canadian Cancer Society Research Institute (CCSRI), and is supported by the Canadian Cancer Society (CCS).

Faculty Researchers

Meet the Faculty Researchers


The information contained in this website is intended for use by Canadian Cancer Trials Group members at participating centres.

Recently Activated

  • ALC6 
    Efficacy of the Addition of Inotuzumab Ozogamicin to Frontline Therapy in Young Adults with Precursor B-Cell ALL
  • BL13 
    Trimodality Therapy With/out Durvalumab to Treat Patients with Muscle-Invasive Bladder Cancer
  • HN10 
    Elective Volume Adjusted De-Escalation Radiotherapy (EVADER) in Patients with Low-risk HPV-related Oropharyngeal SCC
  • HNC2 
    Radiotherapy with Concurrent MEDI4736 vs Radiotherapy with Concurrent Cetuximab in Pts with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin
  • I237 
    A Phase II Study of CFI-400945 in Patients with Advanced/Metastatic Breast Cancer
  • MAC24 
    MK-3475 for Triple Receptor-Negative Breast Cancer with >/= 1 cm Residual Invasive Cancer or Positive Lymph Nodes After Neoadjuvant Chemotherapy
  • PR20 
    Local Ablative Therapy For Hormone Sensitive Oligometastatic Prostate Cancer [PLATON]
  • Planned Trials

  • ALC5 
    Novel Therapeutics vs Azacitidine in Patients with AML or High Risk Myelodysplastic Syndrome, Aged 60 or Older (LEAP, Intergroup Less Intense AML Platform Trial)
  • BRC7 
    INSIGNA: Firstline Immunotherapy alone or in Combination with Chemo in Induction/Maintenance or Post Progression in Adv NSCLC with Immunobiomarker SIGNature-driven Analysis
  • CRC9 
    Circulating Tumor DNA as a Predictive Marker for Response to Chemotherapy in Pts with Stage II Colon Ca
  • I238 
    Durvalumab Retreatment in Patients who Discontinued Prior Checkpoint Therapy Due to Immune Related Toxicity
  • LY18 
    A Phase I Master Protocol of Novel Combination Therapy for Patients with Relapsed or Refractory Aggressive B-Cell Lymphoma
  • MAC25 
    Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2 Positive Metastatic Cancer
  • MAC26 
    Testing the Addition of the Study Drug Olaparib to the Usual Radiotherapy in Inflammatory Breast Cancer Patients